poisar

Stocks · News reference

Lazard Acts as Financial Advisor to Gilead Sciences in $1.275 Billion Acquisition of PepStar Program

Fiscal.ai

Lazard is serving as the financial advisor to Gilead Sciences in its agreement to acquire an investigational oral IL-23R inhibitor program from PepStar Therapeutics Ltd.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading